Vol 12, No 1 (2016)
Case report
Published online: 2016-05-02
Late recurrence of breast cancer in a patient with BRCA1 mutation and subsequent radical treatment for colorectal and endometrial cancer — a case report
Oncol Clin Pract 2016;12(1):19-32.
Abstract
Breast cancer is the most common malignancy in women. Hereditary predisposition is found in 5–10% women with breast cancer and most frequently depends on BRCA1 and BRCA2 mutations. In BRCA1 mutation carriers there is a 56–84% risk of breast cancer and a 36–63% risk of ovarian cancer, while in BRCA2 it is 45–85% and 10–27%, respectively. In both groups there is a 2–3-fold risk of other malignancies. We present a case of a BRCA1 mutation carrier with late relapse of breast cancer after radical treatment for two other malignancies (colorectal and endometrial cancer).
Keywords: breast cancerBRCA1/2 gene mutationslate relapsecolorectal cancerendometrial cancer
References
- Stewart BW, Wild C. World Cancer Report 2014. IARC Nonserial Publication. 2014: 363–374.
- Gronwald J, Byrski T, Huzarski T. Genetyka kliniczna raka piersi i jajnika. In: Lubiński J, Byrski T, Huzarski T. ed. Genetyka kliniczna nowotworów 2012. Pomorski Uniwersytet Medyczny, Szczecin 2012: 69–92.
- Jassem J, Krzakowski M, Bobek-Billewicz B. Rak piersi. In: Krzakowski M, Warzocha K. ed. Zalecenia postępowania diagnostyczno-terapeutycznego w nowotworach złośliwych 2013 rok. Via Medica, Gdańsk 2013: 211–264.
- Jassem J. Rak piersi. In: Krzakowski M, Potemski P, Warzocha K, Wysocki P. ed. Onkologia Kliniczna. Via Medica, Gdańsk 2015: 643–645.
- Górski B, Cybulski C, Huzarski T, et al. Breast cancer predisposing alleles in Poland. Breast Cancer Res Treat. 2005; 92(1): 19–24.
- Gronwald J, Huzarski T, Byrski B, et al. Cancer risks in first degree relatives of BRCA1 mutation carriers: effects of mutation and proband disease status. J Med Genet. 2006; 43(5): 424–428.
- Brożek I, Limon J. Poradnictwo genetyczne w dziedzicznym raku piersi. In: Jassem J, Krzakowski M. ed. Rak piersi. Praktyczny przewodnik dla lekarzy, wydanie II. Via Medica, Gdańsk 2014: 21–23.
- Cavanagh H, Rogers KMA. The role of BRCA1 and BRCA2 mutations in prostate, pancreatic and stomach cancers. Hered Cancer Clin Pract. 2015; 13(1): 16.
- Dawood S, Broglio K, Esteva FJ, et al. Survival among women with triple receptor-negative breast cancer and brain metastases. Ann Oncol. 2009; 20(4): 621–627.
- Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13(15 Pt 1): 4429–4434.
- Metcalfe K, Lynch HT, Ghadirian P, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004; 22(12): 2328–2335.
- Menes TS, Terry MB, Goldgar D, et al. Second primary breast cancer in BRCA1 and BRCA2 mutation carriers: 10-year cumulative incidence in the Breast Cancer Family Registry. Breast Cancer Res Treat. 2015; 151(3): 653–660.
- Molina-Montes E, Pérez-Nevot B, Pollán M, et al. Cumulative risk of second primary contralateral breast cancer in BRCA1/BRCA2 mutation carriers with a first breast cancer: A systematic review and meta-analysis. Breast. 2014; 23(6): 721–742.
- Kirchhoff T, Satagopan JM, Kauff ND, et al. Frequency of BRCA1 and BRCA2 mutations in unselected Ashkenazi Jewish patients with colorectal cancer. J Natl Cancer Inst. 2004; 96(1): 68–70.
- Niell BL, Rennert G, Bonner JD, et al. BRCA1 and BRCA2 founder mutations and the risk of colorectal cancer. J Natl Cancer Inst. 2004; 96(1): 15–21.
- Phelan CM, Iqbal J, Lynch HT, et al. Hereditary Breast Cancer Study Group. Incidence of colorectal cancer in BRCA1 and BRCA2 mutation carriers: results from a follow-up study. Br J Cancer. 2014; 110(2): 530–534.
- Beiner ME, Finch A, Rosen B, et al. Hereditary Ovarian Cancer Clinical Study Group. The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecol Oncol. 2007; 104(1): 7–10.
- Segev Y, Iqbal J, Lubinski J, et al. Hereditary Breast Cancer Study Group. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations: an international prospective cohort study. Gynecol Oncol. 2013; 130(1): 127–131.
- Bruchim I, Amichay K, Kidron D, et al. BRCA1/2 germline mutations in Jewish patients with uterine serous carcinoma. Int J Gynecol Cancer. 2010; 20(7): 1148–1153.